166
Participants
Start Date
June 19, 2020
Primary Completion Date
October 20, 2021
Study Completion Date
December 8, 2021
SCB-2019
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
SCB-2019 with AS03 adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
SCB-2019 with Alum adjuvant
SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
Linear Clinical Research Ltd, Nedlands
Lead Sponsor
Clover Biopharmaceuticals AUS Pty
INDUSTRY